Vincerx Pharma, Inc. Common Stock (NASDAQ:VINC) — Market Cap & Net Worth
Market Cap & Net Worth: Vincerx Pharma, Inc. Common Stock (VINC)
Vincerx Pharma, Inc. Common Stock (NASDAQ:VINC) has a market capitalization of $68.05K ($68.05K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31582 globally and #6338 in its home market, demonstrating a 18.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vincerx Pharma, Inc. Common Stock's stock price $0.02 by its total outstanding shares 5234277 (5.23 Million). Also see VINC total asset value for a full breakdown of the balance sheet.
Vincerx Pharma, Inc. Common Stock Market Cap History: 2020 to 2026
Vincerx Pharma, Inc. Common Stock's market capitalization history from 2020 to 2026. Data shows change from $109.45 Million to $78.51K (-63.97% CAGR). Also see Vincerx Pharma, Inc. Common Stock operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Vincerx Pharma, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #925 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2911 of 3165 |
Weight: Vincerx Pharma, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vincerx Pharma, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vincerx Pharma, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check VINC stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VINC by Market Capitalization
Companies near Vincerx Pharma, Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Vincerx Pharma, Inc. Common Stock to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Vincerx Pharma, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Vincerx Pharma, Inc. Common Stock Historical Marketcap From 2020 to 2026
Between 2020 and today, Vincerx Pharma, Inc. Common Stock's market cap moved from $109.45 Million to $ 78.51K, with a yearly change of -63.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $78.51K | +20.00% |
| 2025 | $65.43K | -95.24% |
| 2024 | $1.38 Million | -77.73% |
| 2023 | $6.18 Million | +15.69% |
| 2022 | $5.34 Million | -89.99% |
| 2021 | $53.34 Million | -51.27% |
| 2020 | $109.45 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Vincerx Pharma, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $68.05K USD |
| MoneyControl | $68.05K USD |
| MarketWatch | $68.05K USD |
| marketcap.company | $68.05K USD |
| Reuters | $68.05K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more